NCCN Announces Research Projects Exploring Axitinib in Various Cancers, in Collaboration with Pfizer

National Comprehensive Cancer Network Oncology Research Program announces selected studies on adding axitinib, an oral VEGF inhibitor, to treatment for melanoma, colorectal cancer, and hepatocellular carcinoma (HCC), in collaboration with Pfizer.